Furthermore, multiple cases of patient relapse involving tumor cells with downregulated BCMA expression have been reported4,5,7, underscoring antigen escape as a significant obstacle in the treatment of MM with BCMA CAR-T cell therapy. Here, TNFRSF17 is linked to Miyoshi myopathy.